Enlivex ENLV 深 沪
等待开盘 06-26 09:30:00 美东时间
0.5804
-0.025
-4.08%
华盛通- 最 高0.66
- 今 开0.61
- 成交量 49.69万股
- 最 低 0.568
- 昨 收 0.6051
- 总市值 1.07万
- 52周最高 2.10
- 市盈率 静 --
- 换手率 2704.57%
- 52周最低 0.568
- 委 比 90.84%
- 总股本 1.84万
- 历史最高 44.90
- 量 比 1.12
- 振 幅 15.20%
- 历史最低 0.568
- 每 手 1
- 风险率 0.20%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Enlivex Holds 79.569B RAIN Token With Total Value Of ~$1.14B
Enlivex Ltd. (NASDAQ:ENLV, "Enlivex" or the "Company")), a quality longevity company powered by a prediction markets treasury, today provided an update on its RAIN token holdings. As of June 20, 2026,
06-22 20:54
Dow Jumps 300 Points; Waldencast Shares Plunge
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gai...
2025-11-25 01:08
D. Boral Capital Downgrades Enlivex Therapeutics to Hold
D. Boral Capital analyst Jason Kolbert downgrades Enlivex Therapeutics (NASDAQ:ENLV) from Buy to Hold.
2025-11-24 23:41
Nasdaq Surges 350 Points; Enlivex Therapeutics Shares Spike Higher
U.S. stocks traded higher this morning, with the Nasdaq Composite gaining more ...
2025-11-24 22:47
Enlivex Therapeutics to Present Clinical Data of Allocetra in Osteoarthritis at EULAR 25 European Congress of Rheumatology
Enlivex Therapeutics will present data on its Allocetra™ therapy for knee osteoarthritis at the EULAR Congress in Barcelona. The presentation will highlight promising results from ongoing Phase I/II trials, including pain reduction and improved joint function, with Phase II data expected by August 2025.
2025-06-10 12:30
HC Wainwright & Co. Reiterates Buy on Enlivex Therapeutics, Maintains $6 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Enlivex Therapeutics (NASDAQ:ENLV) with a Buy and maintains $6 price target.
2024-09-09 18:22
EF Hutton Initiates Coverage On Enlivex Therapeutics with Buy Rating, Announces Price Target of $13
EF Hutton analyst Jason Kolbert initiates coverage on Enlivex Therapeutics (NASDAQ:ENLV) with a Buy rating and announces Price Target of $13.
2024-08-27 20:07
